XML 38 R28.htm IDEA: XBRL DOCUMENT
v3.25.2

Industry Segment Information (Tables) | 6 Months Ended
--- | ---
Jun. 29, 2025
Segment Reporting [Abstract] |
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations | Revenue and operating income, including significant segment expenses, by reportable segment are shown in the table below:
| Three Months Ended
| June 29, 2025 |  | June 30, 2024
| Life Sciences |  | Diagnostics |  | Total |  | Life Sciences |  | Diagnostics |  | Total
| (In thousands)
Segment revenue | $ | 365,898 |  |  | $ | 354,386 |  |  | $ | 720,284 |  |  | $ | 348,525 |  |  | $ | 343,160 |  |  | $ | 691,685 |
Segment cost of revenue | 135,028 |  |  | 156,039 |  |  |  |  | 120,427 |  |  | 146,294 |  |  |
Segment selling, general and administrative expenses | 86,986 |  |  | 84,127 |  |  |  |  | 84,167 |  |  | 83,071 |  |  |
Segment research and development expenses | 28,415 |  |  | 24,798 |  |  |  |  | 26,364 |  |  | 21,046 |  |  |
Segment operating income | $ | 115,469 |  |  | $ | 89,422 |  |  | 204,891 |  |  | $ | 117,567 |  |  | $ | 92,749 |  |  | 210,316 |
Corporate expenses |  |  |  |  | (13,089) |  |  |  |  |  |  | (11,449) |
Amortization of intangible assets |  |  |  |  | (85,289) |  |  |  |  |  |  | (90,620) |
Purchase accounting adjustments |  |  |  |  | (2,178) |  |  |  |  |  |  | (623) |
Acquisition and divestiture-related costs |  |  |  |  | (1,248) |  |  |  |  |  |  | (5,779) |
Significant litigation matters and settlements |  |  |  |  | (1,124) |  |  |  |  |  |  | (6,276) |
Restructuring and other, net |  |  |  |  | (11,203) |  |  |  |  |  |  | (9,845) |
Interest and other (expense) income, net |  |  |  |  | (22,110) |  |  |  |  |  |  | 938 |
Income from continuing operations before income taxes |  |  |  |  | $ | 68,650 |  |  |  |  |  |  | $ | 86,662 |
| Six Months Ended
| June 29, 2025 |  | June 30, 2024
| Life Sciences |  | Diagnostics |  | Total |  | Life Sciences |  | Diagnostics |  | Total
| (In thousands)
Segment revenue | $ | 706,293 |  |  | $ | 678,753 |  |  | $ | 1,385,046 |  |  | $ | 685,039 |  |  | $ | 656,566 |  |  | $ | 1,341,605 |
Segment cost of revenue | 254,349 |  |  | 291,230 |  |  |  |  | 243,988 |  |  | 277,183 |  |  |
Segment selling, general and administrative expenses | 174,081 |  |  | 174,017 |  |  |  |  | 170,104 |  |  | 165,880 |  |  |
Segment research and development expenses | 56,683 |  |  | 50,069 |  |  |  |  | 52,429 |  |  | 44,550 |  |  |
Segment operating income | $ | 221,180 |  |  | $ | 163,437 |  |  | 384,617 |  |  | $ | 218,518 |  |  | $ | 168,953 |  |  | 387,471 |
Corporate expenses |  |  |  |  | (22,904) |  |  |  |  |  |  | (22,810) |
Amortization of intangible assets |  |  |  |  | (167,989) |  |  |  |  |  |  | (181,858) |
Purchase accounting adjustments |  |  |  |  | (2,001) |  |  |  |  |  |  | (7,245) |
Acquisition and divestiture-related costs |  |  |  |  | (3,789) |  |  |  |  |  |  | (17,241) |
Significant litigation matters and settlements |  |  |  |  | (11,710) |  |  |  |  |  |  | (6,276) |
Significant environmental matters |  |  |  |  | 1,208 |  |  |  |  |  |  | — |
Restructuring and other, net |  |  |  |  | (14,442) |  |  |  |  |  |  | (22,201) |
Interest and other expense, net |  |  |  |  | (41,958) |  |  |  |  |  |  | (8,629) |
Income from continuing operations before income taxes |  |  |  |  | $ | 121,032 |  |  |  |  |  |  | $ | 121,211 |
Schedule of Depreciation [Table Text Block] | Depreciation expense included in the Company’s reportable segment operating income and corporate expenses is as follows:
| Three Months Ended |  | Six Months Ended
| June 29, 2025 |  | June 30, 2024 |  | June 29, 2025 |  | June 30, 2024
| (In thousands)
Life Sciences | $ | 8,547 |  |  | $ | 8,124 |  |  | $ | 15,732 |  |  | $ | 16,394 |
Diagnostics | 8,279 |  |  | 7,999 |  |  | 15,125 |  |  | 15,701 |
Corporate | 665 |  |  | 601 |  |  | 1,356 |  |  | 1,192 |
Total depreciation expense | $ | 17,491 |  |  | $ | 16,724 |  |  | $ | 32,213 |  |  | $ | 33,287 |

X
- Definition Schedule of Depreciation + References No definition available. + Details
Name: | revv_ScheduleOfDepreciationTableTextBlock
Namespace Prefix: | revv_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration